Cdk5 as a Drug Target for the Treatment of Alzheimer’s Disease

Author： Lau Lit-Fui   Seymour Patricia A.   Sanner Mark A.   Schachter Joel B.  

Publisher： Humana Press, Inc

ISSN： 0895-8696

Source： Journal of Molecular Neuroscience, Vol.19, Iss.3, 2002-12, pp. : 267-274

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tau as a Drug Target in Alzheimer’s Disease

By Gozes Illana  

Journal of Molecular Neuroscience, Vol. 19, Iss. 3, 2002-12 ,pp. : 337-338

Humana Press, Inc

Access to resources Recommend Favorite

Acetylcholinesterase: A multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer’s disease

By Greenblatt Harry   Dvir Hay   Silman Israel   Sussman Joel  

Journal of Molecular Neuroscience, Vol. 20, Iss. 3, 2003-08 ,pp. : 369-383

Humana Press, Inc

Access to resources Recommend Favorite

The β-secretase, BACE: A prime drug target for Alzheimer’s disease

By Vassar Robert  

Journal of Molecular Neuroscience, Vol. 17, Iss. 2, 2001-10 ,pp. : 157-170

Humana Press, Inc

Access to resources Recommend Favorite

Addressing the complex etiology of Alzheimer’’s disease: the role of p25/Cdk5

By Mungenast Alison E   Tsai Li-Huei  

Future Neurology, Vol. 6, Iss. 4, 2011-07 ,pp. : 481-496

Future Medicine

Access to resources Recommend Favorite

Tuberin – A New Molecular Target in Alzheimer’s Disease?

By Ferrando-Miguel Rosa   Rosner Margit   Freilinger Angelika   Lubec Gert   Hengstschläger Markus  

Neurochemical Research, Vol. 30, Iss. 11, 2005-11 ,pp. : 1413-1419

Springer Publishing Company

Access to resources Recommend Favorite